Copyright Reports & Markets. All rights reserved.

Global Adalimumab Biosimilar Market Research Report 2021

Request for Sample of this report
Buy now

1 Adalimumab Biosimilar Market Overview

  • 1.1 Product Overview and Scope of Adalimumab Biosimilar
  • 1.2 Adalimumab Biosimilar Segment by Type
    • 1.2.1 Global Adalimumab Biosimilar Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Tablet
    • 1.2.3 Oral Solution
  • 1.3 Adalimumab Biosimilar Segment by Application
    • 1.3.1 Adalimumab Biosimilar Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospital Pharmacy
    • 1.3.3 Retail Pharmacy
    • 1.3.4 Online Pharmacy
  • 1.4 Global Adalimumab Biosimilar Market Size Estimates and Forecasts
    • 1.4.1 Global Adalimumab Biosimilar Revenue 2016-2027
    • 1.4.2 Global Adalimumab Biosimilar Sales 2016-2027
    • 1.4.3 Adalimumab Biosimilar Market Size by Region: 2016 Versus 2021 Versus 2027

2 Adalimumab Biosimilar Market Competition by Manufacturers

  • 2.1 Global Adalimumab Biosimilar Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Adalimumab Biosimilar Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Adalimumab Biosimilar Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Adalimumab Biosimilar Manufacturing Sites, Area Served, Product Type
  • 2.5 Adalimumab Biosimilar Market Competitive Situation and Trends
    • 2.5.1 Adalimumab Biosimilar Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Adalimumab Biosimilar Players Market Share by Revenue
    • 2.5.3 Global Adalimumab Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Adalimumab Biosimilar Retrospective Market Scenario by Region

  • 3.1 Global Adalimumab Biosimilar Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Adalimumab Biosimilar Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Adalimumab Biosimilar Market Facts & Figures by Country
    • 3.3.1 North America Adalimumab Biosimilar Sales by Country
    • 3.3.2 North America Adalimumab Biosimilar Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Adalimumab Biosimilar Market Facts & Figures by Country
    • 3.4.1 Europe Adalimumab Biosimilar Sales by Country
    • 3.4.2 Europe Adalimumab Biosimilar Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Adalimumab Biosimilar Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Adalimumab Biosimilar Sales by Region
    • 3.5.2 Asia Pacific Adalimumab Biosimilar Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Adalimumab Biosimilar Market Facts & Figures by Country
    • 3.6.1 Latin America Adalimumab Biosimilar Sales by Country
    • 3.6.2 Latin America Adalimumab Biosimilar Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Adalimumab Biosimilar Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Adalimumab Biosimilar Sales by Country
    • 3.7.2 Middle East and Africa Adalimumab Biosimilar Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Adalimumab Biosimilar Historic Market Analysis by Type

  • 4.1 Global Adalimumab Biosimilar Sales Market Share by Type (2016-2021)
  • 4.2 Global Adalimumab Biosimilar Revenue Market Share by Type (2016-2021)
  • 4.3 Global Adalimumab Biosimilar Price by Type (2016-2021)

5 Global Adalimumab Biosimilar Historic Market Analysis by Application

  • 5.1 Global Adalimumab Biosimilar Sales Market Share by Application (2016-2021)
  • 5.2 Global Adalimumab Biosimilar Revenue Market Share by Application (2016-2021)
  • 5.3 Global Adalimumab Biosimilar Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 AET BioTech
    • 6.1.1 AET BioTech Corporation Information
    • 6.1.2 AET BioTech Description and Business Overview
    • 6.1.3 AET BioTech Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 AET BioTech Product Portfolio
    • 6.1.5 AET BioTech Recent Developments/Updates
  • 6.2 Amgen
    • 6.2.1 Amgen Corporation Information
    • 6.2.2 Amgen Description and Business Overview
    • 6.2.3 Amgen Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Amgen Product Portfolio
    • 6.2.5 Amgen Recent Developments/Updates
  • 6.3 Boehringer Ingelheim
    • 6.3.1 Boehringer Ingelheim Corporation Information
    • 6.3.2 Boehringer Ingelheim Description and Business Overview
    • 6.3.3 Boehringer Ingelheim Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Boehringer Ingelheim Product Portfolio
    • 6.3.5 Boehringer Ingelheim Recent Developments/Updates
  • 6.4 Coherus Biosciences
    • 6.4.1 Coherus Biosciences Corporation Information
    • 6.4.2 Coherus Biosciences Description and Business Overview
    • 6.4.3 Coherus Biosciences Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Coherus Biosciences Product Portfolio
    • 6.4.5 Coherus Biosciences Recent Developments/Updates
  • 6.5 Fujifilm Kyowa Kirin Biologics
    • 6.5.1 Fujifilm Kyowa Kirin Biologics Corporation Information
    • 6.5.2 Fujifilm Kyowa Kirin Biologics Description and Business Overview
    • 6.5.3 Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Fujifilm Kyowa Kirin Biologics Product Portfolio
    • 6.5.5 Fujifilm Kyowa Kirin Biologics Recent Developments/Updates
  • 6.6 LG Life Sciences/Mochida Pharmaceutical
    • 6.6.1 LG Life Sciences/Mochida Pharmaceutical Corporation Information
    • 6.6.2 LG Life Sciences/Mochida Pharmaceutical Description and Business Overview
    • 6.6.3 LG Life Sciences/Mochida Pharmaceutical Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 LG Life Sciences/Mochida Pharmaceutical Product Portfolio
    • 6.6.5 LG Life Sciences/Mochida Pharmaceutical Recent Developments/Updates
  • 6.7 Momenta Pharmaceuticals
    • 6.6.1 Momenta Pharmaceuticals Corporation Information
    • 6.6.2 Momenta Pharmaceuticals Description and Business Overview
    • 6.6.3 Momenta Pharmaceuticals Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Momenta Pharmaceuticals Product Portfolio
    • 6.7.5 Momenta Pharmaceuticals Recent Developments/Updates
  • 6.8 Oncobiologics
    • 6.8.1 Oncobiologics Corporation Information
    • 6.8.2 Oncobiologics Description and Business Overview
    • 6.8.3 Oncobiologics Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Oncobiologics Product Portfolio
    • 6.8.5 Oncobiologics Recent Developments/Updates
  • 6.9 Pfizer
    • 6.9.1 Pfizer Corporation Information
    • 6.9.2 Pfizer Description and Business Overview
    • 6.9.3 Pfizer Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Pfizer Product Portfolio
    • 6.9.5 Pfizer Recent Developments/Updates
  • 6.10 Samsung Bioepsis
    • 6.10.1 Samsung Bioepsis Corporation Information
    • 6.10.2 Samsung Bioepsis Description and Business Overview
    • 6.10.3 Samsung Bioepsis Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Samsung Bioepsis Product Portfolio
    • 6.10.5 Samsung Bioepsis Recent Developments/Updates
  • 6.11 Sandoz
    • 6.11.1 Sandoz Corporation Information
    • 6.11.2 Sandoz Adalimumab Biosimilar Description and Business Overview
    • 6.11.3 Sandoz Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Sandoz Product Portfolio
    • 6.11.5 Sandoz Recent Developments/Updates
  • 6.12 Zydus Cadila
    • 6.12.1 Zydus Cadila Corporation Information
    • 6.12.2 Zydus Cadila Adalimumab Biosimilar Description and Business Overview
    • 6.12.3 Zydus Cadila Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Zydus Cadila Product Portfolio
    • 6.12.5 Zydus Cadila Recent Developments/Updates

7 Adalimumab Biosimilar Manufacturing Cost Analysis

  • 7.1 Adalimumab Biosimilar Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Adalimumab Biosimilar
  • 7.4 Adalimumab Biosimilar Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Adalimumab Biosimilar Distributors List
  • 8.3 Adalimumab Biosimilar Customers

9 Adalimumab Biosimilar Market Dynamics

  • 9.1 Adalimumab Biosimilar Industry Trends
  • 9.2 Adalimumab Biosimilar Growth Drivers
  • 9.3 Adalimumab Biosimilar Market Challenges
  • 9.4 Adalimumab Biosimilar Market Restraints

10 Global Market Forecast

  • 10.1 Adalimumab Biosimilar Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Adalimumab Biosimilar by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Adalimumab Biosimilar by Type (2022-2027)
  • 10.2 Adalimumab Biosimilar Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Adalimumab Biosimilar by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Adalimumab Biosimilar by Application (2022-2027)
  • 10.3 Adalimumab Biosimilar Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Adalimumab Biosimilar by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Adalimumab Biosimilar by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Tablet
    Oral Solution

    Segment by Application
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    AET BioTech
    Amgen
    Boehringer Ingelheim
    Coherus Biosciences
    Fujifilm Kyowa Kirin Biologics
    LG Life Sciences/Mochida Pharmaceutical
    Momenta Pharmaceuticals
    Oncobiologics
    Pfizer
    Samsung Bioepsis
    Sandoz
    Zydus Cadila

    Buy now